Phase 3b Study for Management of Ocular Side Effects in Subjects with EGFR-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414)
Study for Management of Eye Side Effects in Patients with EGFR-Amplified Glioblastoma Receiving ABT-414
Sponsor: AbbVie
Enrolling: Male and Female Patients
IRB Number: AAAR7433
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The main purpose of this study is to improve treatment of ocular side effects that result from depatuxizumab mafodotin (Depatux-M) use in patients with glioblastoma (GBM). Most people treated with Depatux-M will experience eye side effects. When these side effects are not tolerated, Depatux-M is usually interrupted until symptoms improve and then restarted at a lower dose. The use of preventative eye treatment and/or treating the side effect once it occurs may improve the tolerability of these eye side effects, decreasing the need for Depatux-M dose interruptions and dose reductions.
This study is closed
Andrew Lassman, MD
Do You Qualify?
Have you been diagnosed with glioblastoma (GBM) recently? Yes No
Do you have a life expectancy greater than or equal to 3 months? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator